PATENT CLAIM ANALYSIS

Application Number: 15921416
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["435", "006100"]

Abstract:
Biomarkers and methods using the biomarkers for the prediction of the recurrence risk of cancer in a patient are provided.

Claim (Index 27):
A method of treating prostate cancer in a patient comprising: (1) obtaining a sample comprising prostate cancer tumor tissue from said patient; (2) determining by microarray the expression of a panel of genes comprising ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1 and TOP2A in said sample comprising prostate cancer tumor tissue; (3) prognosing said patient as having a decreased likelihood of prostate cancer progression when the average expression of the genes ASF1B, ASPM, BIRC5, BUB1B, C18orf24, CDC2, CDC20, CDCA3, CDCA8, CDKN3, CENPF, CENPM, CEP55, DLGAP5, DTL, FOXM1, KIAA0101, KIF11, KIF20A, MCM10, NUSAP1, ORC6L, PBK, PLK1, PRC1, PTTG1, RAD51, RAD54L, RRM2, TK1 and TOP2A is lower than a threshold index value; and (4) administering to said patient active surveillance based on the prognosis.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.16667
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13819963', '12812215', '15919394', '15588458', '13985470']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5672644408552577
- 35 USC 102 Novelty (BERT): 0.7705901265771359
- Combined Prediction Score: 0.5875970094274456
- Mean Citation Score: 519.695336
- Max Citation Score: 999.20966
- Similarity Product: 897.0310821855114

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test